INBX — Inhibrx Cashflow Statement
0.000.00%
- $1.79bn
- $1.74bn
- $1.80m
Annual cashflow statement for Inhibrx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -51.4 | -76.1 | -81.8 | -145 | -241 |
Depreciation | |||||
Non-Cash Items | 14.7 | 14.4 | 17.8 | 25.5 | 31.5 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 3.48 | 12.7 | -17.5 | 3.16 | 15.3 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -32.1 | -48 | -80.3 | -115 | -193 |
Capital Expenditures | -1.81 | -1.36 | -0.864 | -0.686 | -4.59 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | 0.055 | 0 | — |
Sale of Fixed Assets | |||||
Cash from Investing Activities | -1.81 | -1.36 | -0.809 | -0.686 | -4.59 |
Financing Cash Flow Items | -2.48 | -11.8 | -0.382 | -0.44 | -0.355 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 43.3 | 166 | 83.8 | 259 | 202 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 9.44 | 117 | 2.64 | 143 | 4.06 |